You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

NAPROXEN SODIUM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Naproxen Sodium patents expire, and what generic alternatives are available?

Naproxen Sodium is a drug marketed by Bionpharma, Catalent, Patheon Softgels, Puracap Pharm Llc, Strides Pharma, Actavis Labs Fl Inc, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hamilton Pharms, Hetero Labs Ltd V, Hikma, Ivax Sub Teva Pharms, Lnk Intl Inc, Marksans Pharma, Norvium Bioscience, Novelgenix Theraps, Perrigo, Pld Acquisitions Llc, Pliva, Purepac Pharm, Roxane, Sandoz, Sciegen Pharms Inc, Sun Pharm Inds Ltd, Teva, Teva Pharms, Watson Labs, Yichang Humanwell, Amneal Pharms Co, Corepharma, Granules, P And L, Perrigo R And D, and Aurobindo Pharma. and is included in forty-eight NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifteen patent family members in thirteen countries.

The generic ingredient in NAPROXEN SODIUM is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NAPROXEN SODIUM?
  • What are the global sales for NAPROXEN SODIUM?
  • What is Average Wholesale Price for NAPROXEN SODIUM?
Drug patent expirations by year for NAPROXEN SODIUM
Drug Prices for NAPROXEN SODIUM

See drug prices for NAPROXEN SODIUM

Drug Sales Revenue Trends for NAPROXEN SODIUM

See drug sales revenues for NAPROXEN SODIUM

Recent Clinical Trials for NAPROXEN SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Johnson & Johnson Consumer Inc. (J&JCI)Phase 1
Johnson & Johnson Consumer Inc. (J&JCI)Phase 3
Ciusss de L'Est de l'Île de MontréalN/A

See all NAPROXEN SODIUM clinical trials

Pharmacology for NAPROXEN SODIUM
Paragraph IV (Patent) Challenges for NAPROXEN SODIUM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NAPROXEN SODIUM Capsules naproxen sodium 200 mg 021920 1 2017-11-15

US Patents and Regulatory Information for NAPROXEN SODIUM

NAPROXEN SODIUM is protected by eight US patents.

Patents protecting NAPROXEN SODIUM

Liquid dosage forms of sodium naproxen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TEMPORARY RELIEF OF MINOR ACHES AND PAINS

Liquid dosage forms of sodium naproxen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TEMPORARY REDUCTION OF FEVER

Liquid dosage forms of sodium naproxen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TEMPORARY RELIEF OF MINOR ACHES AND PAINS

Liquid dosage forms of sodium naproxen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TEMPORARY REDUCTION OF FEVER

Liquid dosage forms of sodium naproxen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TEMPORARY RELIEF OF MINOR ACHES AND PAINS

Liquid dosage forms of sodium naproxen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TEMPORARY REDUCTION OF FEVER

Solvent system for enhancing the solubility of pharmaceutical agents
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Liquid dosage forms of sodium naproxen
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Granules NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE diphenhydramine hydrochloride; naproxen sodium TABLET;ORAL 213663-001 Sep 24, 2020 OTC No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074367-001 Aug 31, 1994 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hamilton Pharms NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074106-001 Aug 31, 1993 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Purepac Pharm NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074319-002 Mar 20, 1995 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074198-001 Dec 21, 1993 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pld Acquisitions Llc NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074646-001 Jan 13, 1997 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Roxane NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074257-001 Dec 21, 1993 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NAPROXEN SODIUM

See the table below for patents covering NAPROXEN SODIUM around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1863458 SYSTEME DE SOLVANT DESTINE A AMELIORER LA SOLUBILITE DES AGENTS PHARMACEUTIQUES (SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL AGENTS) ⤷  Sign Up
Denmark 1863458 ⤷  Sign Up
Poland 1863458 ⤷  Sign Up
Slovenia 1863458 ⤷  Sign Up
China 101166520 Solvent system for enhancing the solubility of pharmaceutical agents ⤷  Sign Up
Portugal 1863458 ⤷  Sign Up
Hungary E030784 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NAPROXEN SODIUM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900 122012000052 Germany ⤷  Sign Up PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0984957 122012000051 Germany ⤷  Sign Up PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0984957 PA2011005,C0984957 Lithuania ⤷  Sign Up PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
0984957 CR 2012 00035 Denmark ⤷  Sign Up PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1411900 C300481 Netherlands ⤷  Sign Up PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
1411900 1190013-1 Sweden ⤷  Sign Up PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
1411900 2011/016 Ireland ⤷  Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.